Source-grounded facts extracted from AXIM BIOTECHNOLOGIES, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
AXIM BIOTECHNOLOGIES, INC. underwent a change of control involving Kettner Investments, LLC (closed 2024-10-15).
“Effective October 15, 2024, Juniper & Ivy Corporation (“Juniper”), the holder of all 500,000 shares of the Company's Series C Preferred Stock, entered into an agreement with Medical Marijuana, Inc. ("MJNA") and Kettner Investments, LLC ("Kettner") regarding the transfer and assignment of the Series C Preferred Stock (the "Agreement").”
Catalina Valencia was appointed as Series C Director at AXIM BIOTECHNOLOGIES, INC..
“effective October 14, 2024, Juniper, the record holder of all 500,000 shares of Series C Preferred Stock issued and outstanding, which shares are exclusively entitled to fill any vacancy of a Series C Director seat, appointed Catalina Valencia to fill the Series C Director vacancy”
Catalina Valencia was appointed as President at AXIM BIOTECHNOLOGIES, INC..
“on October 9, 2024, the Company’s board of directors appointed Catalina Valencia as the Company’s new President.”
John W. Huemoeller II departed as Series C Director at AXIM BIOTECHNOLOGIES, INC..
“On October 12, 2024, President and Series C Director, John W. Huemoeller II died as a result of his illness.”
John W. Huemoeller II departed as President and CEO at AXIM BIOTECHNOLOGIES, INC..
“Due to the fact that the Company's President and CEO, John W. Huemoeller II, was unable to serve as an officer of the Company as a result of serious illness”
AXIM BIOTECHNOLOGIES, INC. incurred convertible notes of $814,555 at 4.25% annually maturing March 1, 2034.
“On March 15, 2024, the Company issued unsecured convertible notes with an aggregate face value of $814,555 as more fully described in Item 1.01 above, which is incorporated by reference thereto.”
AXIM BIOTECHNOLOGIES, INC. entered into a notes offering with its independent directors, certain officers and contractors of the Company, and employees of its wholly-owned subsidiary, Sapphire Biotech, Inc. valued at aggregate face value of $814,555 (effective 2024-03-15).
“On March 15, 2024, AXIM Biotechnologies, Inc. (the “Company”) issued Convertible Notes, having an aggregate face value of $814,555 (the "Notes"), to (i) its independent directors for past due director fees, (ii) certain officers and contractors of the Company for past due salaries and fees for services rendered, and (iii) employees of its wholly-owned subsidiary, Sapphire Biotech, Inc. ("Sapphire"), for past due salaries.”
AXIM BIOTECHNOLOGIES, INC. entered into Settlement Agreement with Innovative Medical Supplies, LLC (effective 2024-02-07).
“Effective February 7, 2024, the Company entered into a confidential Global Settlement Agreement and Mutual Release (the “Settlement Agreement”) to resolve the IMS Action as well as a second related action involving many of the same parties.”
AXIM BIOTECHNOLOGIES, INC. entered into Convertible Note Purchase Agreement with Medical Marijuana, Inc valued at $750,000 (effective 2023-12-26).
“Effective December 26, 2023, AXIM Biotechnologies, Inc. (the “Company”) entered into a Convertible Note Purchase Agreement (the "Agreement") with Medical Marijuana, Inc (“MJNA”), currently an affiliate of the Company and one of its largest shareholders, for the purchase of up to $750,000 face value in convertible notes.”
AXIM BIOTECHNOLOGIES, INC. entered into Equity Purchase Agreement with an institutional accredited investor (the "Investor") valued at up to $20,000,000 (effective 2023-06-01).
“On June 1, 2023, AXIM Biotechnologies, Inc., a Nevada corporation (the “Company”), entered into an Equity Purchase Agreement (the “Purchase Agreement”) with an institutional accredited investor (the “Investor”), pursuant to which the Investor committed to purchase up to $20,000,000 of the Company’s common stock (the “Financing”).”
AXIM BIOTECHNOLOGIES, INC. incurred convertible notes of $575,000 with certain investors at 3.75% per annum maturing May 23, 2033.
“On May 23, 2023, AXIM Biotechnologies, Inc. (the “Company”) issued five (5) convertible promissory notes in the aggregate principal amount of $575,000 (the "Convertible Notes") to certain investors.”
Kurt Phinney was appointed as Chief Operating Officer at AXIM BIOTECHNOLOGIES, INC..
“On May 23, 2023, our Chief Executive Officer appointed Kurt Phinney as the Company’s Chief Operating Officer.”
AXIM BIOTECHNOLOGIES, INC. incurred convertible notes of $250,000 with John W. Huemoeller II at 4% per annum maturing January 1, 2033.
“John W. Huemoeller II Settlement Agreement On January 23, 2023, the Company entered into a “Settlement Agreement” with its Chief Executive Officer, John W.”
AXIM BIOTECHNOLOGIES, INC. entered into Convertible Note Modification and Default Waiver Agreement with Medical Marijuana, Inc valued at Face value $4,000,000; interest waived: $261,536.96; conversion price reduced to $0.075; interest ra (effective 2023-01-23).
“On January 23, 2023, the Company and Medical Marijuana, Inc ("MMI") entered into a Convertible Note Modification and Default Waiver Agreement (“MMI Modification Agreement”) in order to modify and cure the default of a convertible note, as amended, face value $4 million, issued by the Company to MMI (the "MMI Convertible Note") as set forth below.”
AXIM BIOTECHNOLOGIES, INC. entered into Settlement Agreement with John W. Huemoeller II valued at Accrued salary of $512,500; $250,000 convertible note issued to Executive at 4% interest, conversion (effective 2023-01-23).
“On January 23, 2023, the Company entered into a “Settlement Agreement” with its Chief Executive Officer, John W. Huemoeller II (the "Executive") regarding $512,500 of accrued and unpaid salary owed to the Executive through December 31, 2022 (the "Amount Due").”
AXIM BIOTECHNOLOGIES, INC. entered into Convertible Notes Modification and Default Waiver Agreement with TL-66 LLC valued at Aggregate face value of Secured Notes: $934,478; interest waived: $216,572; conversion price reduced (effective 2023-01-23).
“On January 23, 2023, AXIM Biotechnologies, Inc. (the “Company”) and TL-66 LLC entered into a Convertible Notes Modification and Default Waiver Agreement (“Waiver Agreement”) in order to modify and cure defaults on various notes issued by the Company and its subsidiaries to TL-66 as summarized below.”
Mauricio Javier Gatto-Bellora resigned as Director at AXIM BIOTECHNOLOGIES, INC..
“consented by written consent in lieu of a meeting appointing Blake N. Schroeder to fill the director seat vacated by the resignation of Mauricio Javier Gatto-Bellora.”
Blake N. Schroeder was appointed as Director at AXIM BIOTECHNOLOGIES, INC..
“consented by written consent in lieu of a meeting appointing Blake N. Schroeder to fill the director seat vacated by the resignation of Mauricio Javier Gatto-Bellora.”
Mauricio Gatto Bellora resigned as member of the Board of Directors at AXIM BIOTECHNOLOGIES, INC..
“On January 4, 2022, Mauricio Gatto Bellora tendered his resignation as a member of the Board of Directors of AXIM Biotechnologies, Inc. (the "Company"), and the Company on that date accepted his resignation.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.